TL;DR: STARMED’s VIVA combo RF System is currently the only RF system in the United States with an FDA-cleared indication specifically for thyroid nodule ablation. That procedure-specific clearance can make thyroid RFA easier to align across documentation, reimbursement, hospital review, and physician referrals.
- STARMED’s FDA clearance specifically names thyroid nodule ablation rather than relying on a broad soft-tissue indication.
- The device label aligns more directly with CPT 60660 and 60661, which may help reduce friction during prior authorization and claims review.
- A thyroid-specific indication can give VAC committees and hospital reviewers a clearer basis for evaluating intended use.
- Referring physicians can more easily understand where the technology fits in a thyroid RFA program.
- STARMED also brings 24 years of global thyroid RFA experience and a large body of supporting clinical literature.
In May 2026, STARMED became the first and currently only company in the United States with an RF system cleared specifically for thyroid nodule ablation. That distinction can make the proposed use easier to explain in clinical documentation and during institutional review, supporting reimbursement discussions moving forward.
Here’s why a thyroid-specific indication really matters for physicians and hospital leaders building thyroid RFA programs today.
A Specific Indication Changes More Than the Label
The FDA 510(k) record identifies the VIVA combo RF System for ultrasound-guided percutaneous ablation of cytologically confirmed benign thyroid nodules in adults. The clearance applies to nodules causing symptoms or cosmetic concerns, as well as autonomously functioning nodules below 10 mL.
Essentially, a general soft-tissue clearance describes a broad category, while STARMED’s clearance names the thyroid procedure, as well as the patients it is intended to treat.
FDA guidance also recognizes that manufacturers and physicians may want a specific indication reflected in labeling for reimbursement and liability purposes.
Why Does Label-to-Code Alignment Matter?
Thyroid RFA now has dedicated Category I thyroid RFA codes, CPT 60660 and 60661. With a thyroid-specific device indication, practices can present a more consistent narrative across three parts of the reimbursement process:
- The patient’s diagnosis and medical necessity in ICD-10 documentation
- The appropriate CPT code for thyroid RFA
- A device label that specifically names thyroid nodule ablation
When those pieces all line up, practices will be able to spend less time explaining why a broadly labeled soft-tissue device is specifically being used for a thyroid procedure. As a result, there will be less friction during prior authorization and claims review (though payer policies will still ultimately determine coverage and payment).
A Clearer Case for VAC and Institutional Review
It’s common for hospital value analysis committees to want to know whether the physician’s intended use matches the device label. Such committees will often review the clinical evidence and operational rationale before approving a new technology.
A thyroid-specific indication provides a clear, direct answer. Rather than relying on a broad soft-tissue interpretation, physicians can point to a cleared indication that specifically supports thyroid nodule ablation.
That may ultimately help with referrals, too. When referring physicians ask whether the technology is intended for thyroid nodules, the answer is likewise a lot more straightforward.
Putting the 2026 Device Rankings in Context
The 2026 device rankings placed STARMED VIVA first overall and described it as the strongest thyroid-specific ecosystem. The review highlighted mature thyroid electrodes and broad representation in the literature, along with STARMED’s training reach and regulatory clarity.
The rankings also make the point that strong technology can’t replace ultrasound skill or thoughtful patient selection, which is why a procedure-specific indication matters, giving qualified physicians a device that is cleared for the procedure they are actually performing.
Build a Stronger Thyroid RFA Program with STARMED
STARMED pairs the only thyroid-specific U.S. FDA indication with 24 years of global thyroid RFA experience and technology cited in more than 300 clinical publications.
The advantages of STARMED RFA technology support reimbursement conversations and help with hospital review. Ultimately, thyroid-specific FDA clearance gives referring physicians a more direct understanding of where the technology fits in.
Review STARMED’s thyroid-specific FDA indication and physician resources to see what this clearance could mean for your thyroid RFA program.
